Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | MGAM | O43451 | 1/20 | 0.58 |
| ▸ | SI | P14410 | 1/20 | 0.58 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28759966 | 0.91 | GAA (0.52) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL1224654 | 0.91 | GAA (0.64) | GAAMGAMSIMGAM2TSHR | |
| Malonic Acid Diethyl Ester SCHEMBL28747435 | 0.89 | GAA (0.75) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL7920381 | 0.88 | TSHR (0.54) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL1981808 | 0.86 | TSHR (0.68) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL19127030 | 0.86 | TSHR (0.52) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL28756040 | 0.84 | GAA (0.67) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL6560703 | 0.84 | TSHR (0.72) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL11246615 | 0.83 | GAA (0.58) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL12561239 | 0.83 | GAA (0.58) | GAAMGAMSIMGAM2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9186325-B2 | Lipids and compositions for the delivery of therapeutics | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-11-17 | — | — | US | disclosed |
| US-9186325-B2 | Lipids and compositions for the delivery of therapeutics | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-11-17 | — | — | US | disclosed |
| US-20110311582-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2011-12-22 | — | — | US | disclosed |
| US-20110311582-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2011-12-22 | — | — | US | disclosed |
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | APODACA RICHARD | 2009-10-22 | — | — | US | disclosed |
| CN-100486970-C | Preparation method of racemic homocitric acid lactone | UNIV XIAMEN (CN) | 2009-05-13 | — | — | CN | disclosed |
| CN-100402513-C | Preparation method of racemic homocitric acid lactone | UNIV XIAMEN (CN) | 2008-07-16 | — | — | CN | disclosed |
| CN-1948299-A | Preparation method of racemic homocitric acid lactone | XIAMEN UIV (CN) | 2007-04-18 | — | — | CN | disclosed |
| CN-1927853-A | Preparation method of racemic homocitric acid lactone | UNIV XIAMEN (CN) | 2007-03-14 | — | — | CN | disclosed |
| EP-0697407-B1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS (JP) | 1997-06-25 | — | — | EP | disclosed |
| EP-0697407-A1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311582-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | APOB, LPAR3, LPAR2 | GAA 3050/4885MGAM 3528/4885SI 1380/4885 |
| US-20090263322-A1 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES | HRH4, HNMT, HRH1 | GAA 1555/4885MGAM 2565/4885SI 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.